Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects.

Theodosia A. Kalfa, Frans A Kuypers, Marilyn J. Telen, Punam Malik, Diamantis G. Konstantinidis, Jeremy H. Estepp, Hyon J. Kim, Santosh L. Saraf, Lindsey Wilson, Maria D Ribadeneira, Sanjeev Forsyth, Patricia Schroeder, Adam Drake, Olga Polyanskaya, Patrick Kelly, Lukasz Biernat. Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects. Blood. 2019 Nov 13; 134(Supplement_1):616-616.